MedTrace Logo

The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma

NCT03242824 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2023-03-14

Study results available
· View outcomes & findings →

Summary

This proposal is for a pilot study comparing volumes of 18F-DOPA-PET avidity with contrast enhancement and T2 FLAIR on MRI. Investigators then plan to compare patterns of failure with target volumes, pre-treatment MRI changes and pre-treatment 18F-DOPA-PET.

Conditions

Interventions

DRUG

Fluorine F 18 Fluorodopa

Contrast used in PET

RADIATION

Intensity-Modulated Radiation Therapy

Radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor

PROCEDURE

Positron Emission Tomography

imaging test

Sponsors & Collaborators

Principal Investigators

  • Nadia N Laack · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-29
Primary Completion
2020-06-16
Completion
2021-06-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03242824 on ClinicalTrials.gov